argenx SE (ARGNF) Stock Price & Analysis
argenx SE (ARGNF) — price $965.00 (0.00%), as of the Nov 18, 2026 trading session; market cap $60.7B.
Educational signal · not a buy or sell recommendation · How to read this
argenx SE · ARGNF · Healthcare · Biotechnology
argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions.
Price as of Nov 18, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $965.00 | |
| Change on the day | 0.00% | |
| 52-week range | $712.02–$1020.00 | |
| Market capitalisation | $60.7B | |
| Price / earnings (trailing) | 44.14 | |
| Shares traded on the day | 49 | |
| Beta (volatility vs the S&P 500) | -0.02 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for argenx SE (ARGNF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is argenx SE (ARGNF), and what does it report?
Short answer · as of
argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. argenx SE (ARGNF) is classified as Healthcare / Biotechnology. SEC filing business address: Industriepark Zwijnaarde 7, Building C B-9052, Zwijnaarde. It employs 1,863 people and is led by Karen Massey. In Q4 FY2026 it reported revenue of $1.72B and net income of $506M. The market values it at $60.7B.
What do the latest results show for argenx SE (ARGNF)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $1.72B. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $1.72B | $506M | $7.80 (diluted) |
| Q2 FY2026 | $2.75B | $820M | $12.74 (diluted) |
| Q4 FY2025 | $2.43B | $883M | $13.34 (diluted) |
| Q2 FY2025 | $948M | $245M | $6.32 (diluted) |
What are the financial strengths and risks for argenx SE (ARGNF)?
Short answer · as of
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway. The distress and quality screens read Altman Z 22.20 · Piotroski F 4. Trailing ratios: ROE 16.9% · ROA 13.2% · current ratio 5.12 · earnings yield 2.2% · free-cash-flow yield 1.8%.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ARGNF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ARGNF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about argenx SE (ARGNF)?
ARGNF Healthcare Stock FAQ
These answers are editorial: 1 of these 8 answers is drawn from the ARGNF research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is ARGNF a good stock to buy?
Stock Expert AI does not rate ARGNF buy, sell or hold. argenx SE has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ARGNF stock price today?
The last price recorded for argenx SE (ARGNF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ARGNF?
The main risks for argenx SE include clinical trial failures for its product candidates, particularly efgartigimod, which is in late-stage development.
What are the key factors to evaluate for ARGNF?
Evaluate ARGNF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Lead product candidate, efgartigimod, in Phase III clinical trials for multiple autoimmune indications, representing near-term revenue potential. Not financial advice.
How frequently does ARGNF data refresh on this page?
ARGNF's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ARGNF's recent stock price performance?
argenx SE (ARGNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platform for antibody development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ARGNF overvalued or undervalued right now?
The trailing P/E of argenx SE (ARGNF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ARGNF before investing?
Before investing in argenx SE (ARGNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com